SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., Evans, T. L., Costa, D., Rosovsky, R., Wakelee, H. A., Heist, R., Shaw, A., Temel, J. S., Shapiro, M. A., Muzikansky, A., Lanuti, M., Lynch, T., Kris, M. G., Sequist, L. V. AMER SOC CLINICAL ONCOLOGY. 2014

View details for Web of Science ID 000358613203950